In Reply We thank Qi and colleagues for their careful review of our article and their thoughtful comments. We agree that the progression-free survival (PFS) of the osimertinib and bevacizumab combination seen in our study1 is comparable to the median PFS with osimertinib alone in the FLAURA study.2 In our article, we note that there was a larger proportion of patients with preexisting brain metastases compared with the FLAURA population (31% vs 19%), and 16% of patients withdrew consent without progression and unrelated to toxic effects to pursue consolidative local therapy (n = 4) or continue with commercial osimertinib (n = 4). These factors may have influenced the PFS in our study.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Schoenfeld AJ, Yu HA. Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers—Reply. JAMA Oncol. 2020;6(12):1983. doi:10.1001/jamaoncol.2020.4824
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: